Neuralstem Enters into Clinical Trial Research Agreement with University of Pennsylvania
News Dec 21, 2007
Neuralstem, Inc. has announced that it has entered into a Clinical Trial Research Agreement aimed at treating patients suffering from Ischemic Spastic Paraplegia, a form of spinal cord paralysis, with the Trustees of the University of Pennsylvania through its Department of Anesthesiology and Critical Care.
The Institution's Principal Investigator is Dr. Albert Cheung, Department of Anesthesiology, Hospital of the University of Pennsylvania.
"We are extremely pleased to be partnering with the University of Pennsylvania Hospital, and Dr. Cheung's team on this important milestone," said Neuralstem President & CEO Richard Garr. "They bring world class experience and talent across the many disciplines that are required for moving into the clinic for our first human trial."
"We at Penn are deeply committed to finding a way to help these patients, and we are excited to be working with Neuralstem's cutting-edge technology," commented Dr. Cheung.
"I am proud to lead this very experienced team that is already at work tackling the important and exciting challenges we face in creating a safe and effective protocol for the first human trials."
Ischemic Spastic Paraplegia (ISP) is a painful form of extreme spasticity and rigidity that causes permanent and untreatable loss of motor function and paralysis. ISP can result from surgery to repair aortic aneurysms, an operation that is performed on thousands of patients each year around the world.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.